Patents by Inventor Susanne Wilde
Susanne Wilde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240083967Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.Type: ApplicationFiled: August 21, 2023Publication date: March 14, 2024Applicant: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian ELLINGER, Carina WEHNER, Manon WEIS, Susanne WILDE, Dolores SCHENDEL
-
Patent number: 11732020Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.Type: GrantFiled: June 16, 2017Date of Patent: August 22, 2023Assignee: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian Ellinger, Carina Wehner, Manon Weis, Susanne Wilde, Dolores Schendel
-
Publication number: 20220401484Abstract: The present invention relates to a T cell receptor (TCR) capable of binding to a PRAME peptide having the amino acid sequence SLLQHLIGL (SEQ ID NO: 1) or a portion thereof, or its HLA-A2 bound form. Also encompassed in the present invention is a nucleic acid encoding a TCR, a vector comprising the nucleic acid, and a host cell comprising the TCR, the nucleic acid sequence, or said vector. Comprised is further, a method for obtaining a TCR described herein, a pharmaceutical or diagnostic composition, and a method of detecting the presence of a cancer in a subject in vitro.Type: ApplicationFiled: November 18, 2020Publication date: December 22, 2022Inventors: Manon Weis, Patrik Kehler, Maria Gerget, Christian Krendl, Susanne Wilde
-
Publication number: 20200339653Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: March 17, 2020Publication date: October 29, 2020Inventors: Dolores Jean SCHENDEL, Susanne WILDE, Bernhard FRANKENBERGER, Wolfgang UCKERT
-
Patent number: 10626159Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding the same, a T cell expressing the TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing the tumor-associated antigen.Type: GrantFiled: November 27, 2017Date of Patent: April 21, 2020Assignees: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN, Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20190169261Abstract: The present invention relates to the field of biotechnology. Specifically, the invention provides antigen-specific T-cell receptors (TCRs). Further, the invention encompasses polynucleotides encoding the same and vectors comprising said polynucleotides. Host cells comprising the molecules of the invention are also provided. Moreover, the invention provides means and methods for diagnostics and therapy, in particular of cancer.Type: ApplicationFiled: June 16, 2017Publication date: June 6, 2019Applicant: MEDIGENE IMMUNOTHERAPIES GMBHInventors: Christian ELLINGER, Carina WEHNER, Manon WEIS, Susanne WILDE, Dolores SCHENDEL
-
Publication number: 20180162921Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: November 27, 2017Publication date: June 14, 2018Inventors: Dolores Jean SCHENDEL, Susanne WILDE, Bernhard FRANKENBERGER, Wolfgang UCKERT
-
Patent number: 9862755Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: GrantFiled: March 25, 2014Date of Patent: January 9, 2018Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20170044233Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.Type: ApplicationFiled: July 7, 2016Publication date: February 16, 2017Inventors: Dolores J. SCHENDEL, Susanne WILDE, Bernhard FRANKENBERGER, Wolfgang UCKERT
-
Patent number: 9409969Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.Type: GrantFiled: February 9, 2010Date of Patent: August 9, 2016Assignees: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZINInventors: Dolores J. Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20140348805Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: March 25, 2014Publication date: November 27, 2014Applicant: Max-Delbrueck-Centrum fur Molekulare Medizin Berlin-BuchInventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20140141026Abstract: The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.Type: ApplicationFiled: July 12, 2013Publication date: May 22, 2014Applicant: Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuR Gesundheit und Umwelt GmbHInventors: Dolores Jean Schendel, Susanne Wilde, Thomas Blankenstein
-
Patent number: 8697854Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: GrantFiled: November 24, 2009Date of Patent: April 15, 2014Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbHInventors: Dolores Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Patent number: 8486694Abstract: The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.Type: GrantFiled: August 4, 2006Date of Patent: July 16, 2013Assignees: Helmholtz Zentrum Muenchen Deutsches Forschungzentrum fuer Gesundheit und Umwelt GmbH, Max-Delbrueck-Centrum fuer Molekulare MedizinInventors: Dolores Schendel, Susanne Wilde, Thomas Blankenstein
-
Publication number: 20120128704Abstract: The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin.Type: ApplicationFiled: February 9, 2010Publication date: May 24, 2012Applicants: Max-Delbrueck-Centrum fuer Molekulare Medizin, HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZEN TRUM FUER GESUNDHEIT UND UMWELT (GMBH)Inventors: Dolores J. Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20110280889Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: November 24, 2009Publication date: November 17, 2011Inventors: Dolores Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20100189728Abstract: The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.Type: ApplicationFiled: August 4, 2006Publication date: July 29, 2010Inventors: Dolores Schendel, Susanne Wilde, Thomas Blankenstein